Yoo-Kang Kwak

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 7

Top Topics

Locally Advanced

Ejection Fraction

Renal Cell Carcinoma

Top Venues

Medicina (Kaunas, Lithuania)

This page only lists publications with an associated author ORCID identifier.

Publications

Hye Jin Kang, Myungsoo Kim, Yoo-Kang Kwak, So Jung Lee
Predictive Factors and the Role of Conventionally Fractionated Radiation Therapy for Bone Metastasis from Renal Cell Carcinoma in the Era of Targeted Therapy. Medicina (Kaunas, Lithuania) 60 (7) (2024)
Soo-Yoon Sung, Sea-Won Lee, Ji Hyung Hong, Hye Jin Kang, So Jung Lee, Myungsoo Kim, Ji Hoon Kim, Yoo-Kang Kwak
Correction: Sung et al. Linear Tumor Regression of Rectal Cancer in Daily MRI during Preoperative Chemoradiotherapy: An Insight of Tumor Regression Velocity for Personalized Cancer Therapy. Cancers 2022, 14 , 3749. Cancers 16 (12) (2024)
Hye Jin Kang, Myungsoo Kim, Yoo-Kang Kwak, So Jung Lee
Predictive Factors and the Role of Conventionally Fractionated Radiation Therapy for Bone Metastasis from Renal Cell Carcinoma in the Era of Targeted Therapy. Medicina (Kaunas, Lithuania) 60 (7) (2024)
So Jung Lee, Myungsoo Kim, Yoo-Kang Kwak, Hye Jin Kang
The Clinical Course of the Late Toxicity of Definitive Radiotherapy in Cervical Cancer. Medicina (Kaunas, Lithuania) 60 (8) (2024)
Hye Jin Kang, Myungsoo Kim, Yoo-Kang Kwak, So Jung Lee
Predictive Factors and the Role of Conventionally Fractionated Radiation Therapy for Bone Metastasis from Renal Cell Carcinoma in the Era of Targeted Therapy. Medicina (Kaunas, Lithuania) 60 (7) (2024)
Soo-Yoon Sung, Sea-Won Lee, Ji Hyung Hong, Hye Jin Kang, So Jung Lee, Myungsoo Kim, Ji Hoon Kim, Yoo-Kang Kwak
Correction: Sung et al. Linear Tumor Regression of Rectal Cancer in Daily MRI during Preoperative Chemoradiotherapy: An Insight of Tumor Regression Velocity for Personalized Cancer Therapy. Cancers 2022, 14 , 3749. Cancers 16 (12) (2024)
Yoo-Kang Kwak, Sea-Won Lee, Chul Seung Kay, Hee Hyun Park
Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose. PloS one 12 (8) (2017)